MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis
Differential diagnosis between Parkinson’s disease (PD) and other Parkinsonism using clinical criteria or imaging methods is often difficult. The purpose of this study is to systematically review and meta-analyze published data about the diagnostic performance of myocardial innervation imaging using 123I-metaiodobenzylguanidine (MIBG) scintigraphy in differential diagnosis between PD and other Parkinsonism.
A comprehensive computer literature search of studies published through March 2011 regarding MIBG scintigraphy in patients with PD and other Parkinsonism was performed in PubMed/MEDLINE and Embase databases. Only studies in which MIBG scintigraphy was performed for differential diagnosis between PD and other Parkinsonism were selected. Pooled sensitivity, pooled specificity and area under the ROC curve were calculated to measure the accuracy of MIBG scintigraphy in differential diagnosis between PD and other Parkinsonism.
Nineteen studies comprising 1,972 patients (1,076 patients with PD, 117 patients with other Lewy body diseases and 779 patients with other diseases) were included in this meta-analysis. The pooled sensitivity of MIBG scintigraphy in detecting PD was 88% (95% CI 86–90%); the pooled specificity of MIBG scintigraphy in discriminating between PD and other Parkinsonism was 85% (95% CI 81–88%). The area under the ROC curve was 0.93.
In patients with clinically suspected PD, myocardial innervation imaging demonstrated high sensitivity and specificity. MIBG scintigraphy is an accurate test in this setting. Nevertheless, possible causes of false-negative and false-positive results should be kept in mind when interpreting the scintigraphic results.
KeywordsMIBG Metaiodobenzylguanidine Parkinson’s disease Parkinsonism Differential diagnosis
- 6.Treglia G, Cason E (2010) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. doi:10.1111/j.1552-6569.2010.00532.x (epub ahead of print)
- 7.Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 105:341–350Google Scholar
- 11.Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230–234PubMedCrossRefGoogle Scholar
- 22.Marini C, Bandettini di Poggio M, Pomposelli E, Marchese R, Nobili F, Morbelli SD, Villa G, Abbruzzese G, Sambuceti G (2010) Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 35:311–316PubMedCrossRefGoogle Scholar
- 23.Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, Haruta H (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord. doi:10.1016/jparkreldis.2011.02.001 (epub ahead of print)
- 31.Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, Mueller J, Sawires M, Scherfler C, Schocke MF, Donnemilier E, Virgolini I, Wenning GK, Poewe W (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771–1776PubMedCrossRefGoogle Scholar
- 43.King AE, Mintz J, Royall DR (2011) Meta-analysis of (123) I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. doi:10.1002/mds.23659
- 48.Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, Somsen GA, Unlu M, Verberne HJ, EANM Cardiovascular Committee; European Council of Nuclear Cardiology (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802–1812PubMedCrossRefGoogle Scholar
- 49.Muxí A, Paredes P, Navales I, Valldeoriola F, Gaig C, Lomeña F, de la Cerda A, Solà O, Domenech B, Tolosa E, Pons F (2011) Diagnostic cutoff points for (123)I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson’s disease. Eur J Nucl Med Mol Imaging 38:1139–1146PubMedCrossRefGoogle Scholar